• By ICR Secretariat
  • Posted Thursday, April 21, 2022

Troubling data leads a biotech to pull its prized drug from market and FDA review


  • The New York-based biotechnology company TG Therapeutics has decided to pull its only approved medicine from the market, after recent clinical trial data showed a potentially increased risk of death in cancer patients who received the drug in combination with one of TG's experimental therapies.